20 results on '"Shahnam, Adel"'
Search Results
2. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies
3. A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials
4. A case for the use of chemotherapy in hereditary mitochondrial optic neuropathies: Successful administration of cisplatin/etoposide in a male patient with testicular seminoma and Leber's hereditary optic neuropathy.
5. Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012–2022.
6. A case for the use of chemotherapy in hereditary optic neuropathies: successful administration of cisplatin/etoposide in a male patient with testicular seminoma and Leber’s Hereditary Optic Neuropathy
7. Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab.
8. Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis
9. Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab
10. Real-World Outcomes of FLOT versus CROSS Regimens for Patients with Oesophagogastric Cancers
11. Haematological and nutritional prognostic biomarkers for patients receiving CROSS or FLOT
12. Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stageIII NSCLCtreated with consolidation durvalumab
13. Growing Teratoma Syndrome in the Setting of Sarcoidosis: A Case Report and Literature Review
14. The prognostic influence of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in stage III non-small cell lung cancer (NSCLC) treated with consolidation durvalumab.
15. The influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
16. Effect of delayed consolidation durvalumab and timing of treatment on survival outcomes in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT).
17. The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy
18. Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab.
19. Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis.
20. Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.